Multimodal Enhanced Recovery After Surgery (ERAS) Program is the Optimal Perioperative Care in Patients Undergoing Totally Laparoscopic Distal Gastrectomy for Gastric Cancer: A Prospective, Randomized, Clinical Trial.

Kang, So Hyun; Lee, Yoontaek; Min, Sa-Hong; Park, Young Suk; Ahn, Sang-Hoon; Park, Do Joong; Kim, Hyung-Ho
Annals of surgical oncology
2018Oct ; 25 ( 11 ) :3231-3238.
저자 상세정보
Kang, So Hyun -
Lee, Yoontaek -
Min, Sa-Hong -
Park, Young Suk -
Ahn, Sang-Hoon -
Park, Do Joong -
Kim, Hyung-Ho -
ABSTRACT
BACKGROUND: The application of ERAS protocol has widely gained acceptance after gastrointestinal surgery. Well-designed, randomized, control trials are needed to evaluate fully its safety and efficacy in the field of gastric cancer. This study aims to compare the enhanced recovery after surgery (ERAS) protocol and the conventional perioperative care program after totally laparoscopic distal gastrectomy (TLDG) in gastric cancer.

METHODS: Patients with gastric cancer indicated for TLDG were randomly assigned to either the ERAS group or the conventional group. The ERAS protocol included short fasting time, fluid restriction, early oral feeding, immediate mobilization, and use of epidural patient-controlled analgesia. Primary endpoint was recovery time, which was defined with the criteria of tolerable diet, safe ambulation, no requirement of additional analgesics, and afebrile state. Hospital stay, pain score, complications, and readmission rate were secondary endpoints.

RESULTS: A total of 97 patients who underwent TLDG from October 2012 to August 2014 were enrolled (ERAS?=?46, conventional?=?51). The ERAS group had faster recovery time (111.6?짹?34.3 vs. 126.7?짹?30.7?h; p?=?0.026) and significantly less pain through postoperative days 1-4. Possible hospital stay also was faster in the ERAS group (5.0?짹?1.9 vs. 5.7?짹?1.6?days, p?=?0.038), but there was no difference in actual hospital stay. No difference was found in complication, and there was no mortality or readmission in both groups.

CONCLUSIONS: ERAS is safe and enhances postoperative recovery after TLDG in gastric cancer. TRIAL REGISTRATION: The trial was registered in ClinicalTrials.gov (NCT01938313).
na
링크

주제코드
주제명(Target field)
연구대상(Population)
연구참여(Sample size)
대상성별(Gender)
질병특성(Condition Category)
연구환경(Setting)
연구설계(Study Design)
연구기간(Period)
중재방법(Intervention Type)
중재명칭(Intervention Name)
키워드(Keyword)
유효성결과(Recomendation)
ERAS is safe and enhances postoperative recovery after TLDG in gastric cancer.
연구비지원(Fund Source)
근거수준평가(Evidence Hierarchy)
출판년도(Year)
참여저자수(Authors)
대표저자
DOI
10.1245/s10434-018-6625-0.
KCD코드
ICD 03
건강보험코드